StockData
OS Therapies Inc logo

OS Therapies Inc (OSTX) stock

OSTXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.74+0.06 (+9.42%)

Close on Nov 17, 2026Market cap $34.35MP/E –Yield –

OS Therapies operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

OS Therapies's operating income for the twelve months ending Jun 30, 2026 was -$37.61M. For fiscal 2025 it was -$28.71M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$28.71M–
FY2024Dec 31, 2024-$6.81M–
FY2023Dec 31, 2023-$4.34M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.58M–
Q1 FY2026Mar 31, 2026-$10.17M–
Q4 FY2025Dec 31, 2025-$11.99M–
Q3 FY2025Sep 30, 2025-$6.88M–
Q2 FY2025Jun 30, 2025-$4.84M–
Q1 FY2025Mar 31, 2025-$5.00M–
Q4 FY2024Dec 31, 2024-$2.97M–
Q3 FY2024Sep 30, 2024-$2.44M–
Q2 FY2024Jun 30, 2024-$779.80K–
Q1 FY2024Mar 31, 2024-$630.23K–
Q4 FY2023Dec 31, 2023-$1.16M–
Q3 FY2023Sep 30, 2023-$622.21K–
Q2 FY2023Jun 30, 2023-$1.52M–
Q1 FY2023Mar 31, 2023-$1.05M–

More OS Therapies figures

See a number that looks wrong?